Precede Biosciences raised $83.5 million in Series B financing and a $20 million credit facility to scale its liquid biopsy platform for pharma collaborations, citing ongoing partnerships across ~30 drug programs. Precede uses RNA‑based NGS and machine learning to profile tumor surface protein expression from blood draws. Adaptive Biotechnologies reported preliminary full‑year revenue up 55% driven by MRD testing (ClonoSeq) growth and delivered record test volumes. The company plans to push MRD adoption across hematologic indications and expand commercial access. Together the financing and commercial growth underline sustained demand from pharma for blood‑based biomarkers and from clinicians/payers for MRD assays, supporting more partner integrations and capacity expansion across diagnostics players.